Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
About this item
Full title
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Author / Creator
Publisher
Springer
Journal title
PharmacoEconomics, 2018, Vol.36 (7), p.867
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying...
Alternative Titles
Full title
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A714601781
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A714601781
Other Identifiers
ISSN
1170-7690
DOI
10.1007/s40273-018-0674-x
How to access this item
Log in as a Library member
